Taken together, our findings not only emphasize the crucial role of FXR in breast cancer metastasis but also investigate its novel regulatory mechanism of ferroptosis through modulation of the CBP-dependent p53 acetylation, which suggest that FXR may function as a potential therapeutic target in metastatic breast cancer. Here, NR1H4 is linked to breast cancer.